BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Guerra Veloz MF, Argüelles-Arias F, Castro Laria L, Maldonado Pérez B, Benítez Roldan A, Perea Amarillo R, Merino Bohórquez V, Calleja MA, Caunedo Álvarez Á, Vilches Arenas Á. Loss of efficacy and safety of the switch from infliximab original to infliximab biosimilar (CT-P13) in patients with inflammatory bowel disease. World J Gastroenterol 2018; 24(46): 5288-5296 [PMID: 30581277 DOI: 10.3748/wjg.v24.i46.5288]
URL: https://www.wjgnet.com/1007-9327/full/v24/i46/5288.htm
Number Citing Articles
Eduardo Mysler, Valderilio Feijó Azevedo, Silvio Danese, Daniel Alvarez, Noriko Iikuni, Beverly Ingram, Markus Mueller, Laurent Peyrin-Biroulet. Biosimilar-to-Biosimilar Switching: What is the Rationale and Current Experience?Drugs 2021; 81(16): 1859 doi: 10.1007/s40265-021-01610-1
Ahmad Zainal Abidin, Centaine L. Snoswell, Leila Shafiee Hanjani, Gavin Callaghan, Michelle Edmonds. Infliximab switching from reference product to biosimilar: a review of evidence regarding the clinical efficacy, safety profile and immunogenicityJournal of Pharmacy Practice and Research 2021; 51(5): 358 doi: 10.1002/jppr.1754
Bincy Abraham, Bertus Eksteen, Khan Nedd, Hrishikesh Kale, Dipen Patel, Jennifer Stephens, Ahmed Shelbaya, Richard Chambers, Arif Soonasra. Impact of Infliximab-dyyb (Infliximab Biosimilar) on Clinical and Patient-Reported Outcomes: 1-Year Follow-up Results from an Observational Real-World Study Among Patients with Inflammatory Bowel Disease in the US and Canada (the ONWARD Study)Advances in Therapy 2022; 39(5): 2109 doi: 10.1007/s12325-022-02104-6
Rosanne W. Meijboom, Helga Gardarsdottir, Toine C. G. Egberts, Thijs J. Giezen. Patients Retransitioning from Biosimilar TNFα Inhibitor to the Corresponding Originator After Initial Transitioning to the Biosimilar: A Systematic ReviewBioDrugs 2022; 36(1): 27 doi: 10.1007/s40259-021-00508-4
Jinjian Huang, Yanhan Ren, Xiuwen Wu, Zongan Li, Jianan Ren. Gut bioengineering promotes gut repair and pharmaceutical research: a reviewJournal of Tissue Engineering 2019; 10: 204173141983984 doi: 10.1177/2041731419839846
Stephanie L. Ho, Fang Niu, Suresh Pola, Fernando S. Velayos, Xian Ning, Rita L. Hui. Effectiveness of Switching from Reference Product Infliximab to Infliximab-Dyyb in Patients with Inflammatory Bowel Disease in an Integrated Healthcare System in the United States: A Retrospective, Propensity Score-Matched, Non-Inferiority Cohort StudyBioDrugs 2020; 34(3): 395 doi: 10.1007/s40259-020-00409-y
Gilaad G Kaplan, Christopher Ma, Cynthia H Seow, Karen I Kroeker, Remo Panaccione. The Argument Against a Biosimilar Switch Policy for Infliximab in Patients with Inflammatory Bowel Disease Living in AlbertaJournal of the Canadian Association of Gastroenterology 2020; 3(5): 234 doi: 10.1093/jcag/gwz044
Natália Sousa Freitas QUEIROZ, Rogerio SAAD-HOSSNE, Renata de Sá Brito FRÓES, Francisco Guilherme Cancela e PENNA, Stefania Burjack GABRIEL, Adalberta Lima MARTINS, Fabio Vieira TEIXEIRA. DISCONTINUATION RATES FOLLOWING A SWITCH FROM A REFERENCE TO A BIOSIMILAR BIOLOGIC IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE: A SYSTEMATIC REVIEW AND META-ANALYSISArquivos de Gastroenterologia 2020; 57(3): 232 doi: 10.1590/s0004-2803.202000000-45